Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001104659-20-038290
Filing Date
2020-03-25
Accepted
2020-03-25 16:16:05
Documents
2
Group Members
DAN OREN

Document Format Files

Seq Description Document Type Size
1 SC 13G tm2013384d1_sc13g.htm SC 13G 49872
2 EXHIBIT 99.1 tm2013384d1_ex99-1.htm EX-99.1 4874
  Complete submission text file 0001104659-20-038290.txt   56471
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401 972-4-988-9488
Protalix BioTherapeutics, Inc. (Subject) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-50118 | Film No.: 20742341
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 1 DEXCEL STREET OR AKIVA L3 3060000
Business Address 1 DEXCEL STREET OR AKIVA L3 3060000 97246364040
Dexcel Pharma Technologies Ltd. (Filed by) CIK: 0001720007 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SC 13G